A six-year real-world analysis from the largest biological treatment center in Poland has confirmed the effectiveness, safety, and retention of secukinumab in managing spondylarthritis (SpA). Published in Scientific Reports, the study offers valuable long-term data for healthcare professionals managing patients with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic SpA.
The retrospective study included 279 adult patients (139 PsA, 112 AS, 28 non-radiographic SpA) who initiated secukinumab treatment between November 2018 and October 2024 through the National Health Fund. Treatment response was observed in 88.2% of patients at 90 days and 88.9% at 180 days, with notable improvements across clinical parameters.
Drug survival at one year was 87%, gradually decreasing to 59% at nearly five years. Dose escalation to 300 mg/month was needed in 32.9% of patients, the majority of whom (77%) showed clinical benefit post-adjustment.
Importantly, the study identified enthesitis as a predictor of treatment failure (OR 2.2; 95% CI 1.05–4.62), while the presence of dactylitis significantly favored continued treatment success (OR 14.69; 95% CI 1.88–114.69).
These findings echo controlled trial results and provide compelling real-world evidence to support the sustained use of secukinumab across SpA subtypes. With high treatment responses and manageable dose adjustments, secukinumab continues to offer a valuable therapeutic option, particularly for patients not responding to TNF inhibitors.
Healthcare professionals are encouraged to consider secukinumab as a durable and effective treatment in the broader landscape of targeted therapies for SpA.
Reference
Felis-Giemza A et al. Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland. Sci Rep. 2025;DOI: 10.1038/s41598-025-11070-2.
